Cambrex continues build-out at former PharmaCore site with $1m investment
The contract manufacturing organization (CMO) has announced plans to fit out 1,300 square feet of analytical laboratory space at the site. As a result, the company expects to hire nine chemical research and development scientists in addition to six analytical research and development scientists.
The expansion also will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments.
Expected to be finished by the end of 2018, the expansion follows a series of investments, the most recently completed of which added 11,000 square feet of analytical laboratory space in April 2018.
In total, Cambrex has invested more than $9m at the site, which it acquired from PharmaCore in 2016.
“Cambrex is seeing a significant increase in new projects, resulting in increased demand for analytical development capabilities within the Cambrex organization,” said Brian Swierenga, VP, operations and site director for Cambrex High Point in a press release.
Last month Cambrex also announced the acquisition of Avista, a move that marked its entrance into the early stage small molecule development and testing market.
The $252m deal is expected to be completed during the fourth quarter of 2018 and will add 300 employees to Cambrex’s staff as well as four facilities.